Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Randomised controlled double-blind trial of DNA ME-TRAP/MVA ME-TRAP against malaria infection in Gambians aged 15 to 45
ISRCTN ISRCTN05221133
ClinicalTrials.gov identifier
Public title Randomised controlled double-blind trial of DNA ME-TRAP/MVA ME-TRAP against malaria infection in Gambians aged 15 to 45
Scientific title
Acronym VAC020
Serial number at source 060147
Study hypothesis A randomised, controlled trial of Deoxyribonucleic Acid (DNA) Multiple Epitope (ME)-Thrombospondin Related Adhesion Protein (TRAP)/Modified Vaccinia virus Ankara (MVA) ME-TRAP in a rural part of Gambia to explore whether this vaccine combination could provide protection against natural P. falciparum infection.
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment Gambia
Disease/condition/study domain Plasmodium falciparum malaria
Participants - inclusion criteria 1. 372 Healthy Gambian men aged 15 to 45
2. Resident in villages in the North Bank Division
Participants - exclusion criteria No exclusion criteria provided at time of registration
Anticipated start date 01/07/2002
Anticipated end date 01/12/2002
Status of trial Completed
Patient information material
Target number of participants 372
Interventions Intervention: Deoxyribonucleic Acid (DNA) Multiple Epitope (ME)-Thrombospondin Related Adhesion Protein (TRAP) malaria vaccination followed by Modified Vaccinia virus Ankara (MVA) ME-TRAP malaria vaccination
Control: Chiron Rabipur rabies vaccine
Primary outcome measure(s) 1. Vaccine safety
2. Immunogenicity
3. Time to first P. falciparum infection
Secondary outcome measure(s) No secondary outcome measures
Sources of funding 1. The Wellcome Trust (UK) (grant ref: 060147)
2. Gates' Partnership at London School of Hygiene and Tropical Medicine (UK)
Trial website
Publications http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15526058
Contact name Dr  Vasee  Moorthy
  Address 6290 Montrose Road
  City/town Rockville
  Zip/Postcode 20814
  Country United States of America
Sponsor London School of Hygiene and Tropical Medicine (UK)
  Address Keppel Street
  City/town London
  Zip/Postcode WC1E 7HT
  Country United Kingdom
Date applied 01/09/2004
Last edited 07/09/2007
Date ISRCTN assigned 05/10/2004
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central